Tectonic Therapeutic, Inc.(TECX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

TECX Tectonic Therapeutic, Inc.

Closed 07-10 16:00:00 EDT

34.37

-0.90

-2.55%

盘后34.37

+0.000.00%

19:17 EDT

High35.58	Low33.86	Vol100.57K
Open35.58	D1 Closing35.27	Amplitude4.88%
Mkt Cap647.82M	Tradable Cap395.91M	Total Shares18.85M
T/O3.47M	T/O Rate0.87%	Tradable Shares11.52M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"TECX","market":"US","secType":"STK","nameCN":"Tectonic Therapeutic, Inc.","latestPrice":34.37,"timestamp":1783713600000,"preClose":35.27,"halted":0,"volume":100567,"hourTrading":{"tag":"盘后","latestPrice":34.37,"preClose":34.37,"latestTime":"19:17 EDT","volume":3085,"amount":106030.15,"timestamp":1783725462985,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":-0.025517436915225563,"floatShares":11519193,"shares":18848500,"eps":-4.458443,"marketStatus":"Closed","change":-0.9,"latestTime":"07-10 16:00:00 EDT","open":35.58,"high":35.58,"low":33.86,"amount":3470547,"amplitude":0.048767,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-4.458443,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1783929600000},"marketStatusCode":5,"adr":0,"listingDate":1529553600000,"exchange":"NASDAQ","adjPreClose":35.27,"postHourTrading":{"tag":"盘后","latestPrice":34.37,"preClose":34.37,"latestTime":"19:17 EDT","volume":3085,"amount":106030.15,"timestamp":1783725462985,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.317082,"impliedVol":0.9535,"impliedVolPercentile":0.4781},"requestUrl":"/m/hq/s/TECX/tweets","defaultTab":"tweets","newsList":[{"id":"2648326521","title":"Tectonic Therapeutic CSO Peter Mcnamara Disposes of USD 6,020 in Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2648326521","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2648326521?lang=en_us&edition=fundamental","pubTime":"2026-07-02 05:20","pubTimestamp":1782940827,"startTime":"0","endTime":"0","summary":"Tectonic Therapeutic CSO Peter McNamara disposes of USD 6,020 in common sharesTectonic Therapeutic Chief Scientific Officer Peter McNamara exercised employee stock options for 172 shares at $14.71 on ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260701:nNDL67MLFP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Tectonic Therapeutic CSO Peter Mcnamara Disposes of USD 6,020 in Common Shares","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","TECX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647309835","title":"Xeris Names CEO John Shannon Board Chair, Effective July 1, 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2647309835","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2647309835?lang=en_us&edition=fundamental","pubTime":"2026-06-30 19:00","pubTimestamp":1782817219,"startTime":"0","endTime":"0","summary":"Xeris names CEO John Shannon board chair, effective July 1, 2026Xeris Biopharma named CEO John Shannon chair of the board, effective July 1, 2026.Marla Persky stepped down as chair, remaining on the b","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260630:nNDL4d2jDk:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","XERS","TECX","TRDA","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642791604","title":"Analysts Offer Insights on Healthcare Companies: Tectonic Therapeutic (TECX) and Stevanato Group (STVN)","url":"https://stock-news.laohu8.com/highlight/detail?id=2642791604","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642791604?lang=en_us&edition=fundamental","pubTime":"2026-06-11 05:20","pubTimestamp":1781126412,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Tectonic Therapeutic (TECX) and Stevanato Group (STV...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-tectonic-therapeutic-tecx-and-stevanato-group-stvn-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-tectonic-therapeutic-tecx-and-stevanato-group-stvn-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","BK4588","TECX","BK4539","BK4121","LABU","STVN","XLV","BK4581","LU0029874061.USD","HCSG","LU0128526141.USD","BK4585","BK4137","XBI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642765034","title":"Tectonic Therapeutic files Form 3 for director Jessica Caroline Chutter","url":"https://stock-news.laohu8.com/highlight/detail?id=2642765034","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642765034?lang=en_us&edition=fundamental","pubTime":"2026-06-11 04:35","pubTimestamp":1781123741,"startTime":"0","endTime":"0","summary":"Tectonic Therapeutic filed an initial statement of beneficial ownership naming Jessica Caroline Chutter as a director on June 10.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tectonic Therapeutic Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on June 10, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260610:nNDL1SShyS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TECX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642475658","title":"Tectonic Therapeutic completes enrollment in TX45 APEX Phase 2 trial for PH-HFpEF patients","url":"https://stock-news.laohu8.com/highlight/detail?id=2642475658","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642475658?lang=en_us&edition=fundamental","pubTime":"2026-06-11 04:01","pubTimestamp":1781121683,"startTime":"0","endTime":"0","summary":"Tectonic Therapeutic completed enrollment in APEX, a Phase 2 trial of TX45 in pulmonary hypertension linked to HFpEF.Topline results have not been presented; readout is expected in early Q1 2027.The study aims to show TX45 can improve disease status in a higher-severity subgroup while supporting an acceptable safety profile.APEX enrolled 191 patients across 14 countries; about 72% were in the enriched CpcPH population.Data from the trial are expected to shape next-step development decisions for TX45 in this indication.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260610:nNDL9hBMsT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2095319765.USD","SG9999014005.SGD","LU0314104364.USD","IE00BKPKM429.USD","LU2210149790.SGD","IE00BN0W2W23.USD","IE00B3QW5Z07.USD","SG9999014039.USD","SG9999014013.SGD","LU2210150020.SGD","IE00BGHQF748.EUR","IE00BN0W2V16.EUR","BK4588","BK4112","IE00BN0W2T93.GBP","BK4139","IE00B64PRP62.GBP","TECX","SG9999014021.USD","BK4585","NDAQ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642847563","title":"Tectonic Therapeutic - Tx45 Apex Phase 2 Topline Results Expected in Early Q1 2027","url":"https://stock-news.laohu8.com/highlight/detail?id=2642847563","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642847563?lang=en_us&edition=fundamental","pubTime":"2026-06-11 04:01","pubTimestamp":1781121660,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260610:nTUA1FN56H:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","TECX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642475633","title":"Tectonic Therapeutic Completes Enrollment in Tx45 Apex Phase 2 Clinical Trial in Ph-Hfpef Patients","url":"https://stock-news.laohu8.com/highlight/detail?id=2642475633","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642475633?lang=en_us&edition=fundamental","pubTime":"2026-06-11 04:01","pubTimestamp":1781121660,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260610:nTUA1FN56H:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","TECX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636078011","title":"Analysts Have Conflicting Sentiments on These Healthcare Companies: Tectonic Therapeutic (TECX) and Urogen Pharma (URGN)","url":"https://stock-news.laohu8.com/highlight/detail?id=2636078011","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636078011?lang=en_us&edition=fundamental","pubTime":"2026-05-18 20:01","pubTimestamp":1779105697,"startTime":"0","endTime":"0","summary":"Analysts have been eager to weigh in on the Healthcare sector with new ratings on Tectonic Therapeutic (TECX) and Urogen Pharma (URGN). Tectonic Th...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-have-conflicting-sentiments-on-these-healthcare-companies-tectonic-therapeutic-tecx-and-urogen-pharma-urgn-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-have-conflicting-sentiments-on-these-healthcare-companies-tectonic-therapeutic-tecx-and-urogen-pharma-urgn-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0029874061.USD","LU0128526141.USD","BK4581","BK4139","XLV","XBI","BK4588","BK4585","URGN","BK4137","TECX","HCSG","LABU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635523066","title":"LifeSci Capital Sticks to Its Buy Rating for Tectonic Therapeutic (TECX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2635523066","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635523066?lang=en_us&edition=fundamental","pubTime":"2026-05-16 22:35","pubTimestamp":1778942135,"startTime":"0","endTime":"0","summary":"LifeSci Capital analyst Gaurav Maini maintained a Buy rating on Tectonic Therapeutic today and set a price target of $88.00. Maini covers the Healt...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/lifesci-capital-sticks-to-its-buy-rating-for-tectonic-therapeutic-tecx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/lifesci-capital-sticks-to-its-buy-rating-for-tectonic-therapeutic-tecx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["TECX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635081485","title":"Oppenheimer Sticks to Its Buy Rating for Tectonic Therapeutic (TECX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2635081485","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635081485?lang=en_us&edition=fundamental","pubTime":"2026-05-15 19:58","pubTimestamp":1778846327,"startTime":"0","endTime":"0","summary":"In a report released today, from Oppenheimer reiterated a Buy rating on Tectonic Therapeutic, with a price target of $80.00. In a report released o...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/oppenheimer-sticks-to-its-buy-rating-for-tectonic-therapeutic-tecx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/oppenheimer-sticks-to-its-buy-rating-for-tectonic-therapeutic-tecx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["OPY","TECX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634443493","title":"LifeSci Capital Remains a Buy on Tectonic Therapeutic (TECX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2634443493","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634443493?lang=en_us&edition=fundamental","pubTime":"2026-05-10 10:09","pubTimestamp":1778378989,"startTime":"0","endTime":"0","summary":"LifeSci Capital analyst Gaurav Maini maintained a Buy rating on Tectonic Therapeutic yesterday and set a price target of $88.00. According to TipRa...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/lifesci-capital-remains-a-buy-on-tectonic-therapeutic-tecx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/lifesci-capital-remains-a-buy-on-tectonic-therapeutic-tecx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["TECX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633513804","title":"Piper Sandler Sticks to Its Buy Rating for Tectonic Therapeutic (TECX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2633513804","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633513804?lang=en_us&edition=fundamental","pubTime":"2026-05-08 21:00","pubTimestamp":1778245241,"startTime":"0","endTime":"0","summary":"Piper Sandler analyst Yasmeen Rahimi maintained a Buy rating on Tectonic Therapeutic today and set a price target of $76.00. Rahimi covers the Heal...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/piper-sandler-sticks-to-its-buy-rating-for-tectonic-therapeutic-tecx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/piper-sandler-sticks-to-its-buy-rating-for-tectonic-therapeutic-tecx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["TECX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633102660","title":"Analysts Are Bullish on These Healthcare Stocks: Tectonic Therapeutic (TECX), Celldex (CLDX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2633102660","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633102660?lang=en_us&edition=fundamental","pubTime":"2026-05-08 09:30","pubTimestamp":1778203813,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Tectonic Therapeutic (TECX), Celldex (CLDX) and Sile...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-these-healthcare-stocks-tectonic-therapeutic-tecx-celldex-cldx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-these-healthcare-stocks-tectonic-therapeutic-tecx-celldex-cldx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4581","BLSG","BK4588","LU0128526141.USD","BK4585","BK4112","BLSX","TECX","XBI","CLDX","BK4139","LABU","LU0029874061.USD","BK4137"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633174112","title":"Tectonic Therapeutic Inc reports results for the quarter ended March 31 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2633174112","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633174112?lang=en_us&edition=fundamental","pubTime":"2026-05-08 04:31","pubTimestamp":1778185873,"startTime":"0","endTime":"0","summary":"Tectonic Therapeutic Inc reports results for the quarter ended March 31 - Earnings SummaryTectonic Therapeutic Inc TECX.OQ reported a quarterly adjusted loss of $1.34 per share for the quarter ended M","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260507:nL8N41K350:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TECX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633745231","title":"Tectonic Therapeutic Q1 EPS $(1.34) Misses $(1.18) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2633745231","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633745231?lang=en_us&edition=fundamental","pubTime":"2026-05-08 04:29","pubTimestamp":1778185782,"startTime":"0","endTime":"0","summary":"Tectonic Therapeutic (NASDAQ:TECX) reported quarterly losses of $(1.34) per share which missed the analyst consensus estimate of $(1.18) by 13.56 percent. This is a 44.09 percent decrease over losses of $(0.93) per share","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/05/52391394/tectonic-therapeutic-q1-eps-1-34-misses-1-18-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Tectonic Therapeutic Q1 EPS $(1.34) Misses $(1.18) Estimate","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","TECX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633176086","title":"Tectonic Therapeutic Q1 net loss widens to $25.2 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2633176086","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633176086?lang=en_us&edition=fundamental","pubTime":"2026-05-08 04:05","pubTimestamp":1778184329,"startTime":"0","endTime":"0","summary":"Tectonic Therapeutic posted a Q1 net loss of USD 25.2 million, widening from a loss of USD 15.9 million a year earlier.R&D expense climbed to USD 20.9 million from USD 13 million, due to CRO and CDMO costs for the ongoing Phase 2 trial of TX45 plus higher employee-related expenses.G&A expense rose to USD 6.4 million from USD 5.3 million.Cash and cash equivalents fell to USD 236.9 million as of March 31, 2026 from USD 253.8 million at year-end, with runway expected into Q4 2028.TX45 APEX Phase 2 enrollment in PH-HFpEF neared completion with topline data expected in late Q4 2026 or early Q1 2027, while TX2100 advanced into Phase 1a with topline results expected by end of Q3 2026.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260507:nNDL1S8LGY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014039.USD","IE00B3QW5Z07.USD","SG9999014021.USD","IE00BN0W2T93.GBP","BK4139","SG9999014005.SGD","TECX","BK4588","IE00B64PRP62.GBP","IE00BGHQF748.EUR","IE00BN0W2W23.USD","NDAQ","LU2095319765.USD","LU2210149790.SGD","LU0314104364.USD","LU2210150020.SGD","IE00BKPKM429.USD","BK4112","IE00BN0W2V16.EUR","BK4585","SG9999014013.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633175068","title":"Press Release: Tectonic Therapeutic Announces First Quarter 2026 Financial Results and Recent Business Highlights","url":"https://stock-news.laohu8.com/highlight/detail?id=2633175068","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633175068?lang=en_us&edition=fundamental","pubTime":"2026-05-08 04:01","pubTimestamp":1778184060,"startTime":"0","endTime":"0","summary":"-- TX45 APEX Phase 2 patient enrollment in PH-HFpEF is nearing completion. with topline results anticipated in late Q4 2026 or early Q1 2027. -- TX2100 advanced into Phase 1a healthy volunteer clinical trial in. February 2026 as a potential treatment for Hereditary Hemorrhagic. Telangiectasia , and as of April 2026, four cohorts have been. -- TX45 ALPINE Phase 2 clinical trial initiated in Pulmonary Hypertension in. Heart Failure associated with Interstitial Lung Disease (\"PH-ILD,\" Group. 3 PH), with first site activated in February 2026 and screening initiated. in March 2026, expanding TX45 into a second pulmonary hypertension. -- Strengthened leadership with the appointment of Franois Nader,M.D., as Chair of the Board and Jessica Chutter, as independent board. director, enhancing governance and strategic oversight as the Company. -- Cash and cash equivalents were $236.9 million as of March 31, 2026,Company initiated dosing in its Phase 1a clinical trial of TX2100 in. ascending-dose t","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","TECX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633716862","title":"Tectonic Therapeutic CMO Marcella Ruddy sells 1,065 shares for $31,950","url":"https://stock-news.laohu8.com/highlight/detail?id=2633716862","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633716862?lang=en_us&edition=fundamental","pubTime":"2026-05-07 05:23","pubTimestamp":1778102605,"startTime":"0","endTime":"0","summary":"Tectonic Therapeutic Chief Medical Officer Marcella K. Ruddy sold 1,065 common shares on May 4 at USD 30.Directly held stake fell to 67,682 shares following transaction.Sale executed under a Rule 10b5-1 trading plan adopted April 8, 2025.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tectonic Therapeutic Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on May 06, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260506:nNDL5V4L9w:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Tectonic Therapeutic CMO Marcella Ruddy sells 1,065 shares for $31,950","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","TECX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632109937","title":"Tectonic Therapeutic Inc  expected to post a loss of $1.18 a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2632109937","media":"Reuters","labels":["preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2632109937?lang=en_us&edition=fundamental","pubTime":"2026-05-04 19:05","pubTimestamp":1777892706,"startTime":"0","endTime":"0","summary":"Tectonic Therapeutic Inc  expected to post a loss of $1.18 a share - Earnings Preview Tectonic Therapeutic Inc TECX.OQ TECX.O is expected to  show no change in quarterly revenue when it reports  resul","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260504:nL8N41H0UT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TECX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630462827","title":"Tectonic Therapeutic announces annual shareholder meeting via virtual webcast","url":"https://stock-news.laohu8.com/highlight/detail?id=2630462827","media":"Reuters","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2630462827?lang=en_us&edition=fundamental","pubTime":"2026-04-25 04:40","pubTimestamp":1777063222,"startTime":"0","endTime":"0","summary":"Tectonic Therapeutic will hold its annual shareholder meeting virtually on June 8, 2026.Shareholders will vote to elect two Class II directors to serve until 2029.Ballots will also cover ratification of Deloitte & Touche as independent auditor for fiscal 2026.An advisory vote will be held on executive compensation for named executive officers.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tectonic Therapeutic Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on April 24, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260424:nNDL38Xdgn:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TECX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.tectonictx.com;investors.tectonictx.com","stockEarnings":[{"period":"1week","weight":-0.0701},{"period":"1month","weight":0.2349},{"period":"3month","weight":0.1481},{"period":"6month","weight":0.7155},{"period":"1year","weight":0.6367},{"period":"ytd","weight":0.6908}],"compareEarnings":[{"period":"1week","weight":0.0093},{"period":"1month","weight":0.0199},{"period":"3month","weight":0.1063},{"period":"6month","weight":0.083},{"period":"1year","weight":0.2045},{"period":"ytd","weight":0.1023}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Tectonic Therapeutic, Inc., a clinical stage biotechnology company focuses on the discovery and development of therapeutic proteins and antibodies to modulate the activity of G-protein coupled receptors(GPCRs). It offers GEODe technology platform to enable the discovery and development of GPCR-targeted biologic medicines. The company's pipeline products include RXFP1 agonist, which is in ongoing phase 1a and 1b for the indication of heart failure with preserved ejection fraction; GPCR antagonist for indication of hereditary hemorrhagic telangiectasia; bi-functional GPCR modulator for indication of fibrosis; and GPCR modulators. Tectonic Therapeutic, Inc. is based in Watertown, Massachusetts.","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":-0.038483},{"month":2,"riseRate":0.5,"avgChangeRate":-0.005058},{"month":3,"riseRate":0.375,"avgChangeRate":-0.012026},{"month":4,"riseRate":0.125,"avgChangeRate":-0.086175},{"month":5,"riseRate":0.75,"avgChangeRate":0.079704},{"month":6,"riseRate":0.25,"avgChangeRate":-0.029433},{"month":7,"riseRate":0.666667,"avgChangeRate":0.119616},{"month":8,"riseRate":0.625,"avgChangeRate":0.020588},{"month":9,"riseRate":0.375,"avgChangeRate":-0.036701},{"month":10,"riseRate":0.875,"avgChangeRate":0.040067},{"month":11,"riseRate":0.5,"avgChangeRate":0.024692},{"month":12,"riseRate":0.5,"avgChangeRate":-0.049184}],"exchange":"NASDAQ","name":"Tectonic Therapeutic, Inc.","nameEN":"Tectonic Therapeutic, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.45.2","shortVersion":"4.45.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Tectonic Therapeutic, Inc.(TECX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Tectonic Therapeutic, Inc.(TECX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Tectonic Therapeutic, Inc.,TECX,Tectonic Therapeutic, Inc.股票,Tectonic Therapeutic, Inc.股票老虎,Tectonic Therapeutic, Inc.股票老虎国际,Tectonic Therapeutic, Inc.行情,Tectonic Therapeutic, Inc.股票行情,Tectonic Therapeutic, Inc.股价,Tectonic Therapeutic, Inc.股市,Tectonic Therapeutic, Inc.股票价格,Tectonic Therapeutic, Inc.股票交易,Tectonic Therapeutic, Inc.股票购买,Tectonic Therapeutic, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Tectonic Therapeutic, Inc.(TECX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Tectonic Therapeutic, Inc.(TECX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction